EnerG2. engineers advanced nano-structured materials for energy storage breakthroughs. EnerG2 is currently focused on customizing electrode materials to enhance energy and power density in ultracapacitors, one of the essential engines of the new energy economy. In the future, EnerG2 materials may be used to improve natural gas, methane and hydrogen storage as well as lithium-ion batteries.

Halosource, Inc. is a bioscience company that employs chitin/chitosan and N-halamine-based technologies to serve the water treatment, biomedical, home, and personal care markets.

Lumera Corp. Located in Bothell, Washington, Lumera develops electro-photonic components based on proprietary polymer materials licensed from the University of Washington.
Initial Public Offering (NasdaqNM: LMRA) 2004

MicroGREEN Polymers, Inc. MicroGREEN is a development stage company focused on advanced polymeric material technologies, headquartered in Arlington, Washington. The company was founded to commercialize a microcellular expanded plastic technology invented at the University of Washington.

Alder Biopharmaceuticals, Inc. Alder's mission is to help alleviate human suffering by generating better and safer antibody therapeutics through novel technologies. Alder plays two roles:

As a biopharmaceutical company, Alder uses its proprietary technologies to uniquely identify, develop, produce and market its own antibody therapeutics. The work being done at Alder today will help those who suffer from cancer, autoimmune diseases, and inflammatory diseases.

As a licensing partner, Alder is revolutionizing the way the pharmaceutical industry discovers, develops and produces antibody therapeutics. Through various licensing agreements, Alder has used its proprietary technology to help major biopharmaceutical partners advance novel therapeutics to the clinic in less time and at lower cost. Alder's licensing strategy also includes identifying a strategic partner to assist in the development and marketing of its lead antibody product, ALD518, for Rheumatoid Arthritis and Cancer.

Accelerator Corp. Accelerator Corporation, founded in 2003, is a vehicle for disciplined and efficient investment in and management of emerging biotechnology opportunities. Located in Seattle, Washington, the company identifies, evaluates, finances, and manages ground breaking emerging life sciences opportunities. The company has established and built a largely proprietary array of sources of deal flow, as well as a key set of resources to bring to bear in the development of the best opportunities emerging from those sources.

Accium BioSciences Accium BioSciences is the first commercial provider of Accelerator Mass Spectrometry (AMS) bioanalytical services in North America.

As a specialty CRO, we provide ultrasensitive quantitation of radiolabeled drugs and their metabolites in clinical samples with routine detection of less than 0.01 DPM in small biological samples.

ARZEDA has the world-leading computational enzyme design technology and is changing the way people think about biocatalysis. ARZEDA was founded by David Baker and three senior members of his lab to commercialize and further develop its computational enzyme design technology. ARZEDA's team includes the inventors of the platform and brings more than 20 years of combined experience in the field of computational and experimental protein engineering.

Corus Pharma, Inc. (Gilead Sciences Inc.) Based in Seattle, Washington, Corus Pharma develops pharmaceutical products that address unmet needs in infectious disease and respiratory disorders. Acquired by Gilead Sciences Inc.

GlobeImmune, Inc. GlobeImmune is a private biopharmaceutical company developing targeted molecular immunogens (Tarmogens) for the treatment of cancer and infectious diseases. GI-5005 is being evaluated in patients with chronic hepatitis C infection (HCV), as both a front-line therapy in combination with standard of care, and as a monotherapy for second line salvage in interferon intolerant patients. GI-4000 is being evaluated in patients with pancreas, lung and colorectal cancers caused by mutations in the Ras oncogene product. To date, Tarmogens have been generally well-tolerated, and shown to generate antigen-specific T cell immune responses and improved clinical outcomes in patients.

Hyperion Therapeutics, Inc. Hyperion Therapeutics, Inc. is a privately held specialty biopharmaceutical company dedicated to improving patients' lives through the development and commercialization of therapies that address critical unmet needs and underserved patient populations. The Company's initial efforts are focused in the areas of gastroenterology and hepatology.

Mirina Corp. Mirina Corp. focuses on the generation of novel microRNA (miRNA) therapeutics with improved properties, such as enhanced target selectivity and higher potency. Mirina’s technology presents promising potential for treating a wide range of diseases, including cancer and a variety of metabolic disorders.

Omeros Omeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Our most clinically advanced product candidates are derived from our proprietary PharmacoSurgery platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Leveraging our clinical development experience and our expertise in inflammation and the central nervous system, we have built multiple development programs targeting large markets. By combining our late-stage PharmacoSurgery product candidates with this deep and diverse pipeline of preclinical development programs, we create multiple opportunities for commercial success. Initial Public Offering filed October 2009.

Targeted Growth, Inc. Targeted Growth, Inc. (TGI) is a crop biotechnology company focused on developing products with enhanced yield and improved quality for the agriculture and energy industries. TGI believes its technologies will become increasingly valuable in the future as the worldwide demand for food and energy crops continues to increase.

VLST Corp. VLST Corp. is a biotechnology company that has developed a novel and streamlined approach to speed the development of effective therapeutics for the treatment of inflammatory and autoimmune diseases. The VLST platform uses novel bioinformatics and state-of-the-art proteomics to identify viral genes whose protein products function as immunomodulatory agents.

Farecast, Inc. This University of Washington start-up uses a combination of techniques to find patterns in the variation of airline ticket prices over time and so predict future price movements. The method may also apply to hotel rooms, rental cars and other analogous markets. Acquired by Microsoft.

Skytap Skytap is the leading provider of cloud-based virtual labs that deliver 100% self-service provisioning of complex IT environments without any architectural changes. Cloud computing is poised to become the defining technology of the 21st century and Skytap's goal is to make serving up virtual machines over the internet as ubiquitous as delivering html to a browser. Depending on how you look at us, we're about maximizing efficiencies, minimizing costs, eliminating unnecessary hardware, outsourcing, eco-efficient computing, and doing more with less.

Corensic Corensic was founded by University of Washington computer science professors Mark Oskin and Luis Ceze to build software to make multi-core computers easier to program and more reliable. The company has been funded by Madrona Ventures and WRF Capital.

Numinous Technologies Inc. Numinous Technologies was founded in 1996 to develop graphics and interactive video software. Among its founders are noted computer graphics scientists David Salesin of the University of Washington and Andries van Dam of Brown University. Acquired by Microsoft.

Performant, Inc. Based in Bellevue, Washington, Performant is developing leading-edge technology to optimize backend performance of enterprise computer systems. The company's Optibench product suite will enable customers to completely outsource the management of their information technology system's performance.

Reality Based Learning Co. A Redmond, Washington based start-up, RBL is developing standards-based educational curriculum and assessment tools delivered through the Internet. The RBL software is based upon 35 years of study by Norris Haring, a founding director of the E.E.U. Center on Human Development and Disability at the University of Washington. Acquired by McGraw-Hill Education.

TeachTown, Inc. Seattle-based TeachTown, Inc. is dedicated to increasing the accessibility of treatments for autism and other learning disabilities. Founded in 2000 by Dr. Christina Whalen, BCBA, TeachTown brings together experts in autism research with experts in video game technology.

EKOS Corp. A Bothell, Washington medical device company, EKOS is developing technologies that use localized ultrasound to facilitate, enhance, or control the delivery or activation of drugs at a targeted tissue site.

Pacific Bioscience Laboratories, Inc. Pacific Bioscience Laboratories, Inc. , a Washington company incorporated in 2001, is the developer of the CLARISONIC™ Skin Care System. The system includes the CLARISONIC brush which uses proprietary sonic technology and a two-way oscillating head to safely, deeply cleanse and clarify the skin. Pacific Bioscience Laboratories' mission is to develop and market technically advanced and clinically proven products that make a clear difference in skin care.

Pathway Medical Technologies, Inc. Pathway Medical Technologies, Inc. was founded to develop, manufacture and market medical devices for the treatment of arterial disease. The company's initial focus is treating peripheral arterial disease (PAD) more quickly, safely and effectively than existing technologies. Pathway's initial product, the Jetstream G2™ is designed to treat the entire spectrum of disease found in the PAD patient including hard and soft plaque, calcium, thrombus, and fibrotic lesions with consistent clinical results.

Mobisante, Inc. Mobisante, Inc. is a privately held mHealth product and services company. Our goal is to make Ultrasound imaging more affordable and accessible to help health care professionals practice better medicine and to reduce costs

Uptake Medical Corp. Uptake Medical Corp. is developing a novel, minimally-invasive lung volume reduction technology for patients suffering from emphysema and other types of chronic obstructive pulmonary diseases (COPD).

Amnis Corp. A Seattle-based start-up founded in 1998, Amnis is developing high throughput laboratory automation tools that use a novel molecule detection technology. The Amnis platform has both molecular and cellular-based applications in research and the clinic.

Intelligent Ion, Inc. Based in Seattle, Washington, Intelligent Ion is developing a miniature mass spectrometer based on proprietary technologies developed at the University of Washington and California Institute of Technology/Jet Propulsion Laboratory. Intelligent Ion is focusing its products for applications in the chemical industry and environmental market. Assets and intellectual property were acquired by O.I. Corp.

nLight Photonics Corp. Based in Vancouver, Washington, nLight Photonics is developing high-powered laser diodes used in industrial applications.

TraceDetect Corp. A Seattle, Washington company founded in 1998 to develop fast, low-cost, portable instruments to detect and measure trace amounts of metals in aqueous solution.

Lucent Medical Systems, Inc. Lucent is designing and developing cost-effective devices which use sensitive magnetic sensors to locate indwelling medical devices.

Ostex International, Inc. Ostex International is engaged in the discovery, development and commercialization of diagnostics and therapeutics for diseases of the skeleton and connective tissues. Ostex was acquired by Inverness Medical Innovations Inc.